The 2025 Menopause Hormone-Therapy Label Reset: Which Warnings Went, Which Stayed, and Why

In November 2025 the U.S. Food and Drug Administration moved to remove the boxed warning that had sat atop menopausal hormone therapy prescribing information for two decades. In plain terms, the statements about cardiovascular disease, breast cancer, and probable dementia are leaving the box at the top of the label, one boxed warning about endometrial cancer stays in place, and the risk information that leaves the box does not leave the document. This is a change to where a warning is printed and how loudly it is stated, not a verdict that hormone therapy is now safe for everyone or a nudge to start it.

Key points#

• The FDA is striking the cardiovascular, breast cancer, and probable dementia language from the boxed warning on menopausal hormone therapy products.
• One boxed warning stays: endometrial cancer with systemic estrogen used alone in women who still have a uterus.
• Cardiovascular and breast cancer information is retained in the label, just outside the box.
• A relocated warning is not a deleted risk.

What a boxed warning actually is#

A boxed warning, still widely called a black box warning, is the strongest safety notice the FDA can require on a prescription medicine. It is reserved for hazards the agency judges serious enough to appear before any other text, framed by a literal black border. That prominence is the point, and also the problem: because a box is read first and remembered longest, it can color how an entire drug class is perceived, sometimes more heavily than the underlying numbers justify.

Taking words out of the box is not the same as erasing the evidence behind them. The agency's own description of the November 2025 action makes clear that cardiovascular and breast cancer information is being kept in the labeling, relocated rather than removed. The question the FDA weighed was placement and emphasis: whether one uniform box, applied to every estrogen product regardless of dose, formulation, or route, still matched what the research showed across women of different ages.

The history behind the box#

To see why the wording is being reconsidered, it helps to remember why the box appeared. It traces to how the Women's Health Initiative (WHI), a large randomized program whose first results landed in the early 2000s, was read at the time. Those early findings drew heavily on one systemic formulation studied largely in women well past the menopausal transition, and they were interpreted as signaling higher rates of cardiovascular events, breast cancer, and cognitive harm. The regulatory answer was a broad, class-wide warning stamped across the category.

Longer follow-up unsettled that first impression. A peer-reviewed analysis of the 2025 action, published in the National Library of Medicine's PubMed Central, summarizes extended WHI data showing that the risk estimates look considerably more favorable when therapy begins in women younger than 60 or within roughly 10 years of menopause onset. In that group the analysis reports no statistically significant rise in coronary heart disease, alongside reductions in all-cause mortality and osteoporotic fractures. Clinicians call this age-and-timing pattern the timing hypothesis. It describes what the trial data show for a defined population; it is not a forecast for any single person.

Which warnings went, and which stayed#

The action, laid out in the FDA press materials and the accompanying Department of Health and Human Services fact sheet, targeted the boxed warning across menopausal hormone therapy products, from systemic formulations to low-dose vaginal preparations. Three risk statements are leaving the box: cardiovascular disease, breast cancer, and probable dementia.

One boxed warning was deliberately spared. The agency did not seek to remove the endometrial cancer warning for systemic estrogen-alone products in women with a uterus. That choice rests on a well-established mechanism: estrogen without a counterbalancing progestogen can stimulate the uterine lining, which is why estrogen-alone regimens are generally avoided in women who have not had a hysterectomy. Keeping that one warning while relocating the rest is the clearest sign that this was a selective edit, not a wholesale clearing of the label.

Local vaginal estrogen was caught in a broad net#

A theme running through the FDA materials is that estrogen products differ sharply in how much medicine actually reaches the bloodstream. Low-dose vaginal estrogen, prescribed for local genitourinary symptoms, is absorbed only in small amounts and acts mainly where it is applied. The peer-reviewed analysis cites a Cochrane review of randomized trials that found no increased risk of endometrial or breast cancer with these local preparations. For years the worry was that stamping a systemic-therapy box onto a locally acting product discouraged its use far beyond what the evidence warranted. The relabeling is meant to correct that mismatch head on.

Why "warning removed" is not "risk removed"#

A headline about a lifted warning is easy to misread as a green light, which is exactly why the boundaries matter. Moving risk language out of the box does not change the case-by-case nature of the decision. Systemic estrogen still carries real risks for some people, and age, symptom burden, other medical conditions, and personal preference all bear on whether it makes sense. The contraindications that applied before November 2025 continue to apply, including a personal history of hormone-sensitive cancer, prior blood clots, and certain cardiovascular events. Those remain matters for a conversation with your clinician, not a label to be scanned in a pharmacy aisle.

In regulatory terms, relocating a warning does not lower the evidentiary bar for any given patient. The same variables that governed the choice before still govern it: how old you are, how long since menopause, how heavy the symptoms, and what the rest of your medical history holds. What changed is the framing you meet first. The tradeoffs the box once compressed into a single alarm are still there to be weighed.

Reading the coverage carefully#

Three distinctions will keep this story in focus for you. First, separate the box from the rest of the label, because text left the box but not the document. Second, separate systemic products from local ones, because how much medicine reaches the bloodstream shapes their risk in different ways. Third, separate a population-level trial signal from an individual prediction, which is precisely the gap a clinician's judgment is meant to fill and a printed warning never could.